Completed NA INTERVENTIONAL NCT00046267

Niacin for Treatment of Elevated Cholesterol and Triglycerides in HIV-Infected Patients

A Pilot Study of the Safety, Efficacy, and Tolerability of Extended-Release Niacin (Niaspan) for the Treatment of Elevated Non-HDL Cholesterol and Elevated Triglycerides in HIV-Infected Subjects

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Conditions Diabetes Mellitus HIV Infections Hypercholesterolemia Hypertriglyceridemia

Interventions Niacin

Updated 6 times since 2017 Last updated: Feb 28, 2011 Primary completion: Dec 31, 2006

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A NA clinical study on Diabetes Mellitus and HIV Infections, this trial is completed. The trial is conducted by National Institute of Allergy and Infectious Diseases (NIAID) and has accumulated 6 data snapshots since 2026. Infectious disease trials contribute critical data for public health response and treatment development.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed NA
Sep 2024 — Sep 2025 [monthly]

Completed NA
Jul 2024 — Sep 2024 [monthly]

Completed NA
Jan 2021 — Jul 2024 [monthly]

Completed NA
Jun 2018 — Jan 2021 [monthly]

Completed NA

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed NA

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Institute of Allergy and Infectious Diseases (NIAID)

Data source: National Institute of Allergy and Infectious Diseases (NIAID)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Cincinnati, United States , Cleveland, United States , Denver, United States , Indianapolis, United States , Los Angeles, United States , Miami, United States , Minneapolis, United States , Pittsburgh, United States , San Diego, United States , St Louis, United States and 1 more location